I'm LongbridgeAI, I can summarize articles.Chernett Jorey increased their stake in Neuronetics (STIM) by purchasing 14,000 shares worth $44,240 on August 17, 2026. This insider buying follows positive Q2 results showing improved revenue, margins, and reduced net loss. Despite ongoing cash burn, the company is shifting to a vertically integrated psychiatry platform via the Greenbrook acquisition. Spark AI rates STIM as Neutral due to weak financial quality, though technicals show strong momentum.
New insider activity at Neuronetics ( (STIM) ) has taken place on August 17, 2026.
Significant shareholder Chernett Jorey has increased their stake in Neuronetics by purchasing 14,000 shares of the company’s stock in a recent transaction, with the total value of the buy amounting to $44,240. This move highlights continued investor interest in Neuronetics and adds a notable block of shares to Jorey’s holdings.
Neuronetics’ shares reacted to Q2 results that showed revenue and margins ahead of expectations, a sharply reduced net loss, and positive adjusted EBITDA, even as cash levels fell and losses persist. These metrics, along with tighter expense guidance and efforts to curb cash burn, underpin recent reassessments of the stock’s outlook.
Analyst views and AI-based assessments also reflect the strategic shift from a pure device model to a vertically integrated interventional psychiatry platform after the Greenbrook acquisition. Leadership changes consolidating financial and governance roles under a new CFO, plus operational initiatives to better monetize NeuroStar and scale Greenbrook clinics, are central to the rationale behind updated price targets and ratings.
Spark’s Take on STIM Stock
According to Spark, TipRanks’ AI Analyst, STIM is a Neutral.
The score is held back primarily by weak financial quality (ongoing losses, negative free cash flow, and high leverage). Technicals are supportive with strong momentum, but overbought signals raise near-term risk. The earnings call data is moderately positive due to better margins and lower cost guidance, yet continued cash burn guidance and execution risk around the NeuroStar transition cap the overall rating.
To see Spark’s full report on STIM stock,
click here.
More about Neuronetics
YTD Price Performance: 139.13%
Average Trading Volume: 2,451,571
Technical Sentiment Signal: Buy
Current Market Cap: $251.5M